Zydus Lifesciences Limited

NSE: ZYDUSLIFE

Healthcare Healthcare

₹1,112.7

+0.04%EOD · 24 Jun

Zydus Lifesciences Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹1.11 L Cr

52W Range

₹1126 / ₹836

Volume

483K

1Y Return

+11.8%

P/E Ratio

21.4

P/B Ratio

4.3

ROE

18.3%

Debt / Equity

42.24

Peers in Healthcare

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Zydus Lifesciences Limited(this stock)	₹1,112.7	₹1.11 L Cr	21.4	4.3	18.3%	0.09%
Divi's Laboratories LimitedDIVISLAB	₹6,734	₹1.79 L Cr	69.8	10.7	16.2%	0.45%
Torrent Pharmaceuticals LimitedTORNTPHARM	₹4,492.5	₹1.53 L Cr	69.4	17.8	17.0%	0.86%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP	₹8,548	₹1.22 L Cr	62.8	12.9	21.5%	0.24%
Max Healthcare Institute LimitedMAXHEALTH	₹1,084.5	₹1.05 L Cr	74.2	9.9	14.3%	0.15%
Mankind Pharma LimitedMANKIND	₹2,540.7	₹1.04 L Cr	52.3	6.1	12.4%	0.08%
Aurobindo Pharma LimitedAUROPHARMA	₹1,539.5	₹88,274 Cr	24.8	2.3	9.9%	0.29%
Laurus Labs LimitedLAURUSLABS	₹1,456.9	₹80,011 Cr	85.5	14.4	17.7%	0.17%
Fortis Healthcare LimitedFORTIS	₹966.5	₹73,389 Cr	70.0	7.3	11.0%	0.10%

Technical Indicators

Full analysis · objective math, not advice

Returns

+0.0%

+2.5%

+2.3%

+18.8%

+27.0%

+11.8%

Weinstein Stage

Stage 2 — Advancing (uptrend)

RSI (14)

94 Overbought

Trend Template

7/7strong

Moving Averages (price vs MA)

20-DMA

₹1082

above

50-DMA

₹1080

above

150-DMA

₹966

above

200-DMA

₹963

above

From 52W High

-1.2%

From 52W Low

+33.2%

Support (20D)

₹1054

Resistance (20D)

₹1126

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+7.3% CAGR

Up 9 of last 11 years

Earnings Quality

Mostly cash-backed

OCF / Net Profit = 0.63x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.